Pernix Announces Fourth Quarter And Full Year 2016 Financial Results
-Fourth Quarter Prescription Volumes Grew Year-Over-Year for All Three Core Brands, Treximet®, Zohydro ER® with BeadTek™ and Silenor®
MORRISTOWN, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial results for the three and twelve months ended December 31, 2016.
MORRISTOWN, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial results for the three and twelve months ended December 31, 2016.